Global Point of Care Diagnostics Market Outlook, 2031
The Global Point of Care Diagnostics Market is segmented into By Product (Glucose Monitoring Kits, Infectious Diseases Testing Kits, Pregnancy And Fertility Testing Kits, Hematology Testing Kits, Cardiometabolic Monitoring Kits, Urinalysis Testing Kits, Cholesterol Test Strips, Other Products); By Technology/Platform (Lateral Flow Assays, Molecular Diagnostics (PCR/INAAT), Microfluidics & Immunoassays, Dipsticks & Test Strips); By End-User (Hospitals & Critical Care Centers, Clinical & Diagnostic Laboratories, Home Care & Self-Testing); By Mode Of Purchase (Prescription Based Products, OTC Products); By Sample (Blood, Urine, Nasal and Oropharyngeal Swabs).
- Bonafide Research
- 23-09-2026
- Pages : 202
- Figures : 36
- Tables : 98
- Region : Global
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The Global Point-of-Care (POC) Diagnostics Market is expected to cross 76.46 Billion market size by 2031, with 8.01% CAGR by 2026-31.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 48.7 Billion
- Market Size (2031) USD 76.46 Billion
- CAGR (2026-2031) 8.01%
- Largest MarketNorth America
- Fastest Market Asia-Pacific
- Format
Featured Companies
- 1. Abbott Laboratories
- 2. Danaher
- 3. F. Hoffmann-La Roche AG,
- 4. LifeScan, Inc
- 5. Nova Biomedical Corporation
- 6. Siemens Healthineers
- 7. OraSure Technologies
- 8. Thermo Fisher Scientific Inc
- 9. QIAGEN N.V.
- More...
Point of Care Diagnostics Market Analysis
The global Point-of-Care (POC) Diagnostics market covers rapid clinical testing performed directly at or near the site of patient care including hospital bedsides, primary care clinics, urgent care centers, community pharmacies, and home environments delivering immediate actionable results without relying on centralized laboratory processing. Growth is driven by the surging global prevalence of chronic illnesses like diabetes and cardiovascular disease, recurring infectious disease outbreaks, an aging global population requiring continuous biomarker monitoring, and rising demand for remote patient monitoring and home-based self-testing. POC diagnostics bridge vital clinical turnaround gaps, enabling clinicians to make immediate therapeutic decisions, reduce emergency room stays, and lower overall healthcare system expenditures. International associations such as the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and the World Health Organization (WHO) play essential roles by establishing global quality control standards, harmonizing regulatory guidelines, and coordinating bulk diagnostic purchasing for public health initiatives across developing nations. Market activities center heavily on technological miniaturization and digital convergence, including the deployment of microfluidic lab-on-a-chip platforms, isothermal molecular PCR assays, and smartphone-connected biosensors integrated with AI-driven analytics and electronic health records (EHR). Additionally, leading medtech companies like Abbott, Roche, Siemens Healthineers, Danaher, and bioMérieux are actively pursuing strategic mergers, localized manufacturing expansions, and regulatory approvals for CLIA-waived over-the-counter testing platforms. Simultaneously, accelerated regulatory pathways such as expanded FDA CLIA-waiver frameworks and streamlined WHO prequalification protocols are making it easier to transition complex diagnostic testing from central reference labs directly to non-laboratory personnel in community clinics and home settings. According to the research report, “Global Point-of-Care (POC) Diagnostics Market Overview, 2031” published by Bonafide Research, the Global Point-of-Care (POC) Diagnostics Market is expected to cross 76.46 Billion market size by 2031, with 8.01% CAGR by 2026-31..The global Point-of-Care (POC) Diagnostics market covers rapid clinical testing conducted directly at or near patient care sites such as hospital emergency rooms, primary clinics, retail pharmacies, and home settings delivering fast, actionable results without central laboratory processing. The global industry is anchored by multinational giants including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, bioMérieux, and Becton, Dickinson and Company (BD), alongside fast-growing regional innovators like Mindray and QIAGEN. Substantial market opportunities center on developing microfluidic lab-on-a-chip cartridges, multiplex isothermal PCR panels for simultaneous pathogen detection, continuous glucose monitoring (CGM) systems, and AI-powered smartphone readers for decentralized remote patient care. Significant corporate developments highlight aggressive innovation, including Abbott continuously expanding its i-STAT and BinaxNOW platforms, Roche integrating cloud-connected cobas point-of-care solutions into electronic health record (EHR) networks, and Danaher’s Cepheid advancing rapid, sample-to-answer molecular diagnostic systems worldwide. Global supply chain analysis reveals a multi-tiered manufacturing architecture: high-precision semiconductors, optical sensors, microfluidic plastic molding, and high-purity biological enzymes are produced across specialized technical hubs in the United States, Western Europe, Japan, and Singapore. High-volume assembly of disposable assay cartridges, lateral-flow test strips, and packaging is heavily concentrated in China, India, and Southeast Asia. To mitigate historical logistics bottlenecks, trade tariffs, and cold-chain distribution risks for delicate reagents, major diagnostic manufacturers are increasingly nearshoring production facilities, expanding regional warehousing hubs, and establishing localized supply networks across high-growth markets worldwide.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Global surge in chronic disease burden and rapid demographic aging: The expanding global burden of chronic non-communicable conditions most notably type 2 diabetes, cardiovascular diseases, renal disorders, and chronic respiratory conditions serves as the primary long-term growth engine for the POC diagnostics market. Coupled with a rapidly aging global population, healthcare systems face unprecedented volume demands for continuous biomarker monitoring. Conditions like diabetes require daily, ongoing blood glucose and periodic HbA1c testing, while acute cardiovascular events necessitate rapid bedside troponin and blood gas evaluations. Point-of-care testing enables frequent monitoring directly at hospital bedsides, ambulatory care units, or patient homes, providing immediate clinical data that allows physicians to optimize treatment regimens within minutes.• Systemic health system shift toward decentralized, value-based care: Global healthcare systems are aggressively transitioning away from high-cost, centralized inpatient hospital stays toward decentralized, value-based primary and ambulatory care networks. Traditional centralized laboratory workflows involve multi-step sample collection, transport, processing, and batch reporting, introducing turnaround delays ranging from several hours to multiple days. POC diagnostic platforms eliminate these logistics delays by delivering lab-grade diagnostic results directly during a single patient visit. By facilitating rapid clinical decision-making in physician offices, urgent care centers, and emergency rooms, POC diagnostics reduce emergency department length-of-stay, prevent unnecessary hospital readmissions, streamline isolation protocols for contagious pathogens, and significantly lower overall health administration expenses.
Market Challenges
• Analytical accuracy benchmarks, sample matrix interference, and quality control risks: Achieving analytical accuracy, sensitivity, and specificity comparable to high-throughput centralized clinical laboratory analyzers remains a major technical and operational challenge for portable POC systems. Because point-of-care tests are frequently performed by non-laboratory personnel such as nurses, medical assistants, or patients themselves they are highly susceptible to operator variability, improper sample collection techniques (e.g., micro-clotting in capillary whole-blood samples), and environmental interference (such as ambient temperature and humidity fluctuations).• Complex regulatory cleardown pathways and reimbursement fragmentation: Commercializing point-of-care diagnostic platforms globally requires navigating complex, highly stringent regulatory environments that vary significantly across international jurisdictions. In major markets like the United States, transitioning a diagnostic device from prescription laboratory use to a CLIA-waived or over-the-counter (OTC) home setting demands extensive clinical trial documentation proving high diagnostic performance when operated by untrained users. Simultaneously, the European Union's IVDR framework has increased clinical evidence mandates and created severe certification bottlenecks with Notified Bodies.
Market Trends
• Miniaturization via microfluidics, multiplexing, and isothermal molecular assays: The global POC market is undergoing a decisive technological evolution from traditional, single-analyte lateral-flow immunoassay strips to advanced microfluidic "lab-on-a-chip" cartridges and rapid isothermal molecular PCR platforms. Miniaturized microfluidic channels manipulate microliter volumes of whole blood or saliva to perform complex chemical pre-treatments, mixing, and optical analysis automatically within a closed plastic disposable cartridge. Concurrently, modern point-of-care molecular systems utilize isothermal nucleic acid amplification (e.g., LAMP) rather than heavy thermal cyclers, allowing healthcare workers to run multiplex panels that screen a single patient sample for multiple respiratory, gastrointestinal, or sexually transmitted pathogens simultaneously within 15 to 30 minutes.• Digital health convergence: Point-of-care diagnostic hardware is rapidly converging with mobile health (mHealth) connectivity, artificial intelligence, and cloud software infrastructure. Contemporary handheld analyzers and smartphone-connected diagnostic readers incorporate Bluetooth, Wi-Fi, and cloud API integrations that automatically stream patient test results into centralized Electronic Health Record (EHR) systems and hospital information platforms in real time. Embedded AI algorithms are increasingly deployed to interpret subtle optical or electrochemical assay outputs, eliminating subjective human interpretation errors and ensuring consistent diagnostic scoring.
Point of Care Diagnostics Segmentation
| By Product | Glucose Monitoring Kits | |
| Infectious Diseases Testing Kits | ||
| Pregnancy And Fertility Testing Kits | ||
| Hematology Testing Kits | ||
| Cardiometabolic Monitoring Kits | ||
| Urinalysis Testing Kits | ||
| Cholesterol Test Strips | ||
| Other Products | ||
| By Technology/Platform | Lateral Flow Assays | |
| Molecular Diagnostics (PCR/INAAT) | ||
| Microfluidics & Immunoassays | ||
| Dipsticks & Test Strips | ||
| By End-User | Hospitals & Critical Care Centers | |
| Clinical & Diagnostic Laboratories | ||
| Home Care & Self-Testing | ||
| By Mode Of Purchase | Prescription Based Products | |
| OTC Products | ||
| By Sample | Blood | |
| Urine | ||
| Nasal and Oropharyngeal Swabs | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
Glucose monitoring kits are the largest product segment because diabetes requires frequent blood-glucose measurement, making glucose meters and test strips routine point-of-care tools across homes, clinics, pharmacies, and healthcare facilities. Glucose monitoring has a particularly strong position within point-of-care diagnostics because diabetes management depends on repeated measurement rather than a one-time diagnostic test. The World Health Organization identifies blood-glucose meters and related technologies as important devices for diabetes diagnosis and monitoring, and its Essential Diagnostics List includes glucose testing among diagnostics that can be used in primary-care and community settings. The clinical need is substantial: the CDC reported that during August 2021-August 2023, 15.8% of U.S. adults had total diabetes, including diagnosed and undiagnosed disease, illustrating the continuing need for glucose assessment and disease management. Canada likewise reports millions of people living with diagnosed diabetes, reinforcing the importance of regular glucose monitoring across North American healthcare systems. Unlike many point-of-care tests that are performed only when symptoms or a specific clinical question arise, glucose monitoring can be repeated according to an individual's treatment plan, making meters and strips recurring-use diagnostic products. The FDA describes blood-glucose monitoring systems as devices used in both homes and healthcare settings and explains that the system typically combines a handheld meter with test strips that analyze a small blood sample. This combination also makes glucose monitoring highly adaptable to different care environments. Patients can perform testing at home, while healthcare professionals can use similar technologies in clinics and other care settings. WHO's 2023 Essential Diagnostics List specifically added recommendations concerning personal-use glucose monitoring devices alongside existing diabetes diagnostic recommendations, further demonstrating the recognized role of these products in self-management. WHO's 2025 work on diabetes technologies also specifically examines blood-glucose meters, test strips and lancets as essential technologies for diabetes management, emphasizing their availability, affordability, safety and quality. Dipsticks and test strips are the largest technology/platform segment because they provide rapid, simple, portable testing with minimal equipment requirements and can be adapted to numerous diagnostic applications across decentralized healthcare settings. Dipsticks and test strips occupy an important position in point-of-care diagnostics because they convert diagnostic procedures into relatively simple workflows that can be performed close to the patient. WHO's Essential Diagnostics List specifically recognizes urine dipsticks and other simple diagnostic formats for primary-care and community settings, where laboratory infrastructure may be limited. The practical advantage is that many strip-based tests require only the specimen, the strip and, depending on the product, visual interpretation or a small reader, avoiding the need for sophisticated laboratory equipment. This makes the technology suitable for health facilities, pharmacies, community programmes and selected home-testing applications. WHO has repeatedly emphasized the value of point-of-care diagnostics because testing near the patient can support faster treatment decisions, reduce referrals and improve efficiency, particularly where laboratory infrastructure is weak. Dipstick technology also covers multiple clinical applications rather than one disease area. Urinalysis strips can evaluate parameters such as glucose, protein, blood, ketones, leukocytes, nitrites and pH, while other strip formats are used for pregnancy and infectious-disease testing. The FDA's CLIA database, for example, lists numerous waived urine reagent-strip systems covering several analytes, illustrating how established strip-based testing is within U.S. point-of-care practice. Glucose monitoring provides another major application of strip technology because handheld meters generally use disposable test strips to analyze a small blood sample. The FDA explains that blood-glucose monitoring systems combine a meter and test strips, demonstrating how strip-based consumables are integrated into a widely used point-of-care workflow. Strip formats also have logistical advantages: they can be packaged individually or in containers, transported relatively easily and used without large analyzers. Their relatively straightforward operation makes them useful where trained laboratory personnel are unavailable, although the exact level of training depends on the test. WHO's diagnostic guidance stresses that quality assurance, appropriate product selection and correct use remain essential because simplicity does not eliminate the possibility of incorrect results. Hospitals and critical care centers are the largest end-user segment because they require rapid diagnostic information to make immediate decisions about emergency treatment, patient monitoring, medication, infection management and acute clinical deterioration. Hospitals and critical care centers represent a natural environment for point-of-care diagnostics because many clinical decisions cannot wait for conventional laboratory turnaround times. WHO notes that point-of-care testing can be performed near the patient and can help optimize treatment decisions, avoid referrals and improve efficiency of care. These advantages become particularly important in emergency departments, intensive care units, operating rooms and other areas where clinicians manage patients whose condition can change quickly. In such environments, tests for glucose, blood gases, electrolytes, hemoglobin, coagulation parameters, infectious diseases and other indicators can provide information during the clinical encounter. The value is not simply that results are fast; it is that the result can be connected immediately to a treatment decision. A clinician may use a glucose result to guide management, assess a critically ill patient's metabolic status, or determine whether additional testing is necessary. Hospitals also have the infrastructure to integrate point-of-care testing into established clinical governance systems. Unlike a consumer setting, hospital testing can be connected to trained personnel, quality-control procedures, electronic medical records, clinical protocols and confirmatory laboratory services. This makes hospitals well suited to adopting a wide variety of point-of-care technologies, including both simple waived tests and more sophisticated instrument-based systems. The FDA's CLIA framework demonstrates that point-of-care testing includes both home-use glucose devices and prescription-use systems intended for professional healthcare settings such as hospitals, physician offices and long-term-care facilities. Critical care also creates frequent testing requirements because patients may need repeated measurements throughout their treatment. This differs from screening environments where a test may be performed only once. Repeated testing increases the practical value of systems that can deliver results directly at the bedside. Hospitals additionally encounter large numbers of patients with different diagnostic requirements, giving point-of-care platforms a wide application base. WHO's Essential Diagnostics List is structured around different levels of healthcare, including facilities with laboratories and community or primary-care settings, reflecting the fact that diagnostic requirements vary according to clinical complexity. OTC products are the largest mode-of-purchase segment because many point-of-care diagnostic products are designed for direct consumer access, particularly for home monitoring, screening and recurring self-testing. Over-the-counter access is closely associated with the broader shift toward patient participation in routine health monitoring. Point-of-care diagnostics are no longer limited to hospitals and laboratories; selected tests can be used by individuals in homes, pharmacies and community settings without a conventional clinical visit. WHO recognizes self-care interventions that include diagnostic and monitoring technologies, while its Essential Diagnostics List includes tests intended for community settings and self-testing. Blood-glucose monitoring is a clear example of this model. The FDA specifically regulates self-monitoring blood-glucose systems intended for OTC home use by lay users and distinguishes them from prescription point-of-care systems intended for professional healthcare settings. The FDA also explains that blood-glucose monitoring devices can be used in the home and healthcare settings and that the system consists of a handheld meter and test strips. This demonstrates why OTC purchasing can be particularly relevant for products that are repeatedly used by individuals managing chronic conditions. Consumers do not necessarily need a healthcare facility each time they need to measure glucose or perform another authorized home test. OTC access can therefore reduce friction between recognizing a need for testing and obtaining the diagnostic product. The category also includes familiar consumer-oriented tests such as pregnancy tests and selected rapid diagnostic products, although availability and regulatory status vary considerably by country and test. WHO's diagnostic framework separates community/self-testing environments from laboratory settings and emphasizes that countries should determine appropriate diagnostic access based on their healthcare systems, disease burden and regulatory conditions. OTC availability also supports decentralized healthcare because consumers can obtain tests through retail pharmacies, online channels and other authorized distribution routes, depending on national regulations. Repeated-use products further strengthen this purchasing pathway because consumers may need replacement strips, lancets or test kits over time. However, OTC access does not mean that professional care becomes unnecessary. A positive or abnormal result may require confirmation, clinical interpretation or treatment, and product instructions must be followed carefully. WHO emphasizes the importance of quality, safety, affordability and appropriate use of diagnostic products. The significance of OTC products therefore comes from their ability to place selected diagnostic tools directly into consumers' hands while supporting ongoing monitoring and early identification of health concerns. As healthcare increasingly incorporates self-management and decentralized testing, direct consumer purchasing provides a practical distribution mechanism for suitable point-of-care products. Blood is the largest sample segment because blood provides direct access to clinically important biomarkers and is routinely used for glucose, hemoglobin, coagulation, infectious-disease and other point-of-care measurements. Blood is particularly important in point-of-care diagnostics because it contains a wide range of measurable indicators that can directly inform diagnosis and treatment. WHO's Essential Diagnostics List includes numerous tests based on blood specimens and identifies blood-based diagnostics across community, primary-care and laboratory settings. A major reason for the prominence of blood is glucose monitoring. Handheld blood-glucose meters typically analyze a small blood sample applied to a disposable test strip, allowing patients or healthcare professionals to obtain a glucose measurement within the point-of-care workflow. The FDA describes this system explicitly and recognizes blood-glucose monitoring devices for both home and healthcare settings. Blood is also used for hemoglobin measurement, which can support assessment of anemia, and for a variety of infectious-disease and other diagnostic tests. The ability to measure several clinically important analytes from a relatively small sample makes blood highly adaptable to different point-of-care platforms. Capillary blood obtained through a fingerstick is especially useful for decentralized testing because collection can be performed quickly without venous phlebotomy for suitable tests. This is one reason blood-based point-of-care testing can be incorporated into pharmacies, primary-care clinics, emergency environments and home monitoring. WHO has emphasized the importance of diagnostics that can be used at the primary-care level, including glucometers and other tests that can function where laboratory infrastructure is limited. Blood testing also supports rapid clinical decisions. In an emergency or critical-care environment, immediate measurements can help clinicians assess metabolic abnormalities, monitor treatment and determine whether additional intervention is needed. At the same time, blood-based point-of-care testing is not limited to acute care; chronic diseases such as diabetes require repeated blood-glucose monitoring over extended periods. WHO's 2025 review of diabetes technologies specifically covers blood-glucose meters, test strips and lancets, highlighting their role in diabetes management and the need for safe, quality-assured and affordable access. The sample's versatility also allows point-of-care manufacturers to develop different platforms around whole blood, plasma or other blood-derived specimens depending on the diagnostic application. Blood therefore has an unusually broad connection to both chronic and acute healthcare.
to Download this information in a PDF
Point of Care Diagnostics Market Regional Insights
North America is the largest region because the region combines high healthcare utilization, established diagnostic infrastructure, substantial chronic-disease monitoring needs, and mature regulatory and reimbursement systems that support widespread point-of-care testing. North America's position is strongly associated with the depth of its healthcare infrastructure and the established integration of diagnostic testing into routine medical care. The United States has extensive hospital, physician-office, pharmacy and outpatient networks, while Canada operates a publicly funded healthcare system with broad access to primary and hospital services. Chronic disease provides an important underlying need for repeated diagnostics. CDC data show that total diabetes affected 15.8% of U.S. adults during August 2021-August 2023, with diagnosed and undiagnosed diabetes both contributing to the total. Canada also reports millions of people living with diagnosed diabetes, demonstrating that diabetes monitoring is an established healthcare requirement across the region. Point-of-care diagnostics fit these systems because they can provide results close to the patient and support treatment decisions without always requiring specimens to travel to centralized laboratories. WHO describes point-of-care testing as a way to optimize treatment decisions, avoid referrals and improve care efficiency. The United States also has a mature regulatory framework for decentralized laboratory testing through CLIA. FDA's CLIA database contains extensive listings of waived glucose monitoring devices and urine reagent-strip systems, demonstrating the breadth of point-of-care technologies authorized for use under waived testing conditions. This regulatory infrastructure supports standardized requirements around test performance and appropriate use. North America also benefits from strong consumer familiarity with home diagnostics. • USA: The United States represents the largest regional component because it combines a very large healthcare delivery infrastructure with extensive use of regulated point-of-care testing across hospitals, clinics, physician offices, pharmacies, and home settings. The United States has several structural characteristics that support extensive use of point-of-care diagnostics within North America. One is the scale and diversity of its healthcare delivery system, which includes hospitals, outpatient clinics, physician offices, long-term-care facilities, emergency departments, pharmacies, and home-based care.
to Download this information in a PDF
Key Development
- August 2026QuidelOrtho Corporation expanded its point-of-care molecular diagnostics portfolio following its April acquisition of LEX Diagnostics, whose LEX VELO System had received FDA 510(k) clearance and CLIA waiver in February. The ultra-fast PCR platform is designed to deliver multiplex results for Influenza A, Influenza B, and COVID-19 directly from a swab in approximately 6-10 minutes, with QuidelOrtho expecting a US commercial launch later in 2026. The acquisition and commercialization plan represent a major development directly focused on Point of Care Diagnostics.
- June 2026F. Hoffmann-La Roche Ltd. obtained FDA clearance for an updated cobas® pulse blood glucose monitoring system, with the FDA decision dated June 12, 2026. The professional blood-glucose system is designed for near-patient testing across hospital and professional healthcare settings and integrates mobile digital-health capabilities and connectivity with Roche's navify® POC solutions. The regulatory clearance represents a substantive 2026 development directly involving a point-of-care diagnostic platform.
- May 2025Roche expanded its cobas liat point-of-care PCR testing portfolio to strengthen rapid decentralized infectious disease diagnostics.
- June 2026bioMérieux submitted a dual FDA 510(k)/CLIA-waiver application for the BIOFIRE® SPOTFIRE® Vaginitis Panel, an automated multiplex PCR test designed to simultaneously detect common causes of vaginitis in approximately 20 minutes directly at the point of care. The submission expands the SPOTFIRE platform into women's and sexual health and represents a substantive regulatory and product-development milestone directly related to Point of Care Diagnostics.
- February 2026Abram Scientific secured $11.75M in Series A funding led by Octapharma AG. The investment supports development of the portable CoagCare platform for rapid point-of-care coagulation testing in trauma and surgical settings.
- February 2026Athelas received FDA clearance for its CLIA-waived, AI-powered Athelas Home hematology analyzer. The point-of-care device delivers white blood cell counts and neutrophil percentages from fingerstick samples in minutes for use in clinics, pharmacies, and home settings.
- February 2026LEX Diagnostics gained FDA clearance and CLIA waiver for the VELO system, a rapid molecular diagnostics platform. It provides PCR results for respiratory pathogens in under 10 minutes from swabs, enabling point-of-care deployment in the US.
- February 2026QuidelOrtho signed a supply agreement to broaden its global immunoassay portfolio with advanced analyzer platforms and assays. This enhances point-of-care diagnostic capabilities for expanded international market access.
- November 2025Sapphiros entered into a collaboration with Roche granting access to its $1B potential instrument-free multiplex molecular platform for affordable point-of-care testing with lab-quality results.
- January 2025Abbott continued expanding its Point of Care diagnostics portfolio with rapid diagnostic solutions for cardiometabolic, infectious disease, and emergency care applications.
- November 2025Sciverse Solutions and Bhat Biotech in India announced a strategic collaboration to co-develop AI-enabled molecular diagnostic platforms, advancing portable point-of-care testing with real-time, high-accuracy results.
Companies Mentioned
- Abbott Laboratories
- Danaher
- F. Hoffmann-La Roche AG,
- LifeScan, Inc
- Nova Biomedical Corporation
- Siemens Healthineers
- OraSure Technologies
- Thermo Fisher Scientific Inc
- QIAGEN N.V.
- QuidelOrtho Corporation
- Becton, Dickinson and Company
- Sysmex Corporation
- Sekisui Medical Co., Ltd.
- bioMérieux
- EKF Diagnostics
- Werfen S.A.
- Trinity Biotech
- Trividia Health
- HemoCue
- Chembio Diagnostics
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Global Point of Care Diagnostics Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Region
- 6.3. Market Size and Forecast, By Geography
- 6.4. Market Size and Forecast, By Product
- 6.5. Market Size and Forecast, By Technology/Platform
- 6.6. Market Size and Forecast, By End-User
- 6.7. Market Size and Forecast, By Mode Of Purchase
- 6.8. Market Size and Forecast, By Sample
- 7. North America Point of Care Diagnostics Market Outlook
- 7.1. Market Size By Value
- 7.2. Market Share By Country
- 7.3. Market Size and Forecast, By Product
- 7.4. Market Size and Forecast, By Technology/Platform
- 7.5. Market Size and Forecast, By End-User
- 7.6. Market Size and Forecast, By Mode Of Purchase
- 7.7. Market Size and Forecast, By Sample
- 7.8. United States Point of Care Diagnostics Market Outlook
- 7.8.1. Market Size by Value
- 7.8.2. Market Size and Forecast By Product
- 7.8.3. Market Size and Forecast By Technology/Platform
- 7.8.4. Market Size and Forecast By End-User
- 7.9. Canada Point of Care Diagnostics Market Outlook
- 7.9.1. Market Size by Value
- 7.9.2. Market Size and Forecast By Product
- 7.9.3. Market Size and Forecast By Technology/Platform
- 7.9.4. Market Size and Forecast By End-User
- 7.10. Mexico Point of Care Diagnostics Market Outlook
- 7.10.1. Market Size by Value
- 7.10.2. Market Size and Forecast By Product
- 7.10.3. Market Size and Forecast By Technology/Platform
- 7.10.4. Market Size and Forecast By End-User
- 8. Europe Point of Care Diagnostics Market Outlook
- 8.1. Market Size By Value
- 8.2. Market Share By Country
- 8.3. Market Size and Forecast, By Product
- 8.4. Market Size and Forecast, By Technology/Platform
- 8.5. Market Size and Forecast, By End-User
- 8.6. Market Size and Forecast, By Mode Of Purchase
- 8.7. Market Size and Forecast, By Sample
- 8.8. Germany Point of Care Diagnostics Market Outlook
- 8.8.1. Market Size by Value
- 8.8.2. Market Size and Forecast By Product
- 8.8.3. Market Size and Forecast By Technology/Platform
- 8.8.4. Market Size and Forecast By End-User
- 8.9. United Kingdom (UK) Point of Care Diagnostics Market Outlook
- 8.9.1. Market Size by Value
- 8.9.2. Market Size and Forecast By Product
- 8.9.3. Market Size and Forecast By Technology/Platform
- 8.9.4. Market Size and Forecast By End-User
- 8.10. France Point of Care Diagnostics Market Outlook
- 8.10.1. Market Size by Value
- 8.10.2. Market Size and Forecast By Product
- 8.10.3. Market Size and Forecast By Technology/Platform
- 8.10.4. Market Size and Forecast By End-User
- 8.11. Italy Point of Care Diagnostics Market Outlook
- 8.11.1. Market Size by Value
- 8.11.2. Market Size and Forecast By Product
- 8.11.3. Market Size and Forecast By Technology/Platform
- 8.11.4. Market Size and Forecast By End-User
- 8.12. Spain Point of Care Diagnostics Market Outlook
- 8.12.1. Market Size by Value
- 8.12.2. Market Size and Forecast By Product
- 8.12.3. Market Size and Forecast By Technology/Platform
- 8.12.4. Market Size and Forecast By End-User
- 8.13. Russia Point of Care Diagnostics Market Outlook
- 8.13.1. Market Size by Value
- 8.13.2. Market Size and Forecast By Product
- 8.13.3. Market Size and Forecast By Technology/Platform
- 8.13.4. Market Size and Forecast By End-User
- 9. Asia-Pacific Point of Care Diagnostics Market Outlook
- 9.1. Market Size By Value
- 9.2. Market Share By Country
- 9.3. Market Size and Forecast, By Product
- 9.4. Market Size and Forecast, By Technology/Platform
- 9.5. Market Size and Forecast, By End-User
- 9.6. Market Size and Forecast, By Mode Of Purchase
- 9.7. Market Size and Forecast, By Sample
- 9.8. China Point of Care Diagnostics Market Outlook
- 9.8.1. Market Size by Value
- 9.8.2. Market Size and Forecast By Product
- 9.8.3. Market Size and Forecast By Technology/Platform
- 9.8.4. Market Size and Forecast By End-User
- 9.9. Japan Point of Care Diagnostics Market Outlook
- 9.9.1. Market Size by Value
- 9.9.2. Market Size and Forecast By Product
- 9.9.3. Market Size and Forecast By Technology/Platform
- 9.9.4. Market Size and Forecast By End-User
- 9.10. India Point of Care Diagnostics Market Outlook
- 9.10.1. Market Size by Value
- 9.10.2. Market Size and Forecast By Product
- 9.10.3. Market Size and Forecast By Technology/Platform
- 9.10.4. Market Size and Forecast By End-User
- 9.11. Australia Point of Care Diagnostics Market Outlook
- 9.11.1. Market Size by Value
- 9.11.2. Market Size and Forecast By Product
- 9.11.3. Market Size and Forecast By Technology/Platform
- 9.11.4. Market Size and Forecast By End-User
- 9.12. South Korea Point of Care Diagnostics Market Outlook
- 9.12.1. Market Size by Value
- 9.12.2. Market Size and Forecast By Product
- 9.12.3. Market Size and Forecast By Technology/Platform
- 9.12.4. Market Size and Forecast By End-User
- 10. South America Point of Care Diagnostics Market Outlook
- 10.1. Market Size By Value
- 10.2. Market Share By Country
- 10.3. Market Size and Forecast, By Product
- 10.4. Market Size and Forecast, By Technology/Platform
- 10.5. Market Size and Forecast, By End-User
- 10.6. Market Size and Forecast, By Mode Of Purchase
- 10.7. Market Size and Forecast, By Sample
- 10.8. Brazil Point of Care Diagnostics Market Outlook
- 10.8.1. Market Size by Value
- 10.8.2. Market Size and Forecast By Product
- 10.8.3. Market Size and Forecast By Technology/Platform
- 10.8.4. Market Size and Forecast By End-User
- 10.9. Argentina Point of Care Diagnostics Market Outlook
- 10.9.1. Market Size by Value
- 10.9.2. Market Size and Forecast By Product
- 10.9.3. Market Size and Forecast By Technology/Platform
- 10.9.4. Market Size and Forecast By End-User
- 10.10. Colombia Point of Care Diagnostics Market Outlook
- 10.10.1. Market Size by Value
- 10.10.2. Market Size and Forecast By Product
- 10.10.3. Market Size and Forecast By Technology/Platform
- 10.10.4. Market Size and Forecast By End-User
- 11. Middle East & Africa Point of Care Diagnostics Market Outlook
- 11.1. Market Size By Value
- 11.2. Market Share By Country
- 11.3. Market Size and Forecast, By Product
- 11.4. Market Size and Forecast, By Technology/Platform
- 11.5. Market Size and Forecast, By End-User
- 11.6. Market Size and Forecast, By Mode Of Purchase
- 11.7. Market Size and Forecast, By Sample
- 11.8. United Arab Emirates (UAE) Point of Care Diagnostics Market Outlook
- 11.8.1. Market Size by Value
- 11.8.2. Market Size and Forecast By Product
- 11.8.3. Market Size and Forecast By Technology/Platform
- 11.8.4. Market Size and Forecast By End-User
- 11.9. Saudi Arabia Point of Care Diagnostics Market Outlook
- 11.9.1. Market Size by Value
- 11.9.2. Market Size and Forecast By Product
- 11.9.3. Market Size and Forecast By Technology/Platform
- 11.9.4. Market Size and Forecast By End-User
- 11.10. South Africa Point of Care Diagnostics Market Outlook
- 11.10.1. Market Size by Value
- 11.10.2. Market Size and Forecast By Product
- 11.10.3. Market Size and Forecast By Technology/Platform
- 11.10.4. Market Size and Forecast By End-User
- 12. Competitive Landscape
- 12.1. Competitive Dashboard
- 12.2. Business Strategies Adopted by Key Players
- 12.3. Key Players Market Share Insights and Analysis, 2025
- 12.4. Key Players Market Positioning Matrix
- 12.5. Porter's Five Forces
- 12.6. Company Profile
- 12.6.1. Abbott
- 12.6.1.1. Company Snapshot
- 12.6.1.2. Company Overview
- 12.6.1.3. Financial Highlights
- 12.6.1.4. Geographic Insights
- 12.6.1.5. Business Segment & Performance
- 12.6.1.6. Product Portfolio
- 12.6.1.7. Key Executives
- 12.6.1.8. Strategic Moves & Developments
- 12.6.2. F. Hoffmann-La Roche Ltd.
- 12.6.3. Siemens Healthineers AG
- 12.6.4. QuidelOrtho Corporation
- 12.6.5. Danaher
- 12.6.6. Becton, Dickinson and Company
- 12.6.7. Thermo Fisher Scientific
- 12.6.8. BioMérieux
- 12.6.9. EKF Diagnostics
- 12.6.10. QIAGEN
- 12.6.11. Werfen S.A.
- 12.6.12. OraSure Technologies
- 12.6.13. Trinity Biotech
- 12.6.14. Nova Biomedical
- 12.6.15. Sekisui Diagnostics
- 12.6.16. Trividia Health
- 12.6.17. Sysmex Corporation
- 12.6.18. HemoCue
- 12.6.19. Chembio Diagnostics
- 12.6.20. LifeScan
- 13. Strategic Recommendations
- 14. Annexure
- 14.1. FAQ`s
- 14.2. Notes
- 15. Disclaimer
Table 2: Influencing Factors for Point of Care Diagnostics Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Point of Care Diagnostics Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 8: Global Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 9: Global Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 10: Global Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 11: Global Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 12: North America Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 13: North America Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 14: North America Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 15: North America Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 16: North America Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 17: United States Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 18: United States Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 19: United States Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 20: Canada Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 21: Canada Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 22: Canada Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 23: Mexico Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 24: Mexico Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 25: Mexico Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 26: Europe Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 27: Europe Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 28: Europe Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 29: Europe Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 30: Europe Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 31: Germany Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 32: Germany Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 33: Germany Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 34: United Kingdom (UK) Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 35: United Kingdom (UK) Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 36: United Kingdom (UK) Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 37: France Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 38: France Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 39: France Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 40: Italy Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 41: Italy Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 42: Italy Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 43: Spain Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 44: Spain Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 45: Spain Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 46: Russia Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 47: Russia Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 48: Russia Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 49: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 50: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 51: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 52: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 53: Asia-Pacific Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 54: China Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 55: China Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 56: China Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 57: Japan Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 58: Japan Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 59: Japan Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 60: India Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 61: India Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 62: India Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 63: Australia Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 64: Australia Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 65: Australia Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 66: South Korea Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 67: South Korea Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 68: South Korea Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 69: South America Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 70: South America Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 71: South America Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 72: South America Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 73: South America Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 74: Brazil Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 75: Brazil Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 76: Brazil Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 77: Argentina Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 78: Argentina Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 79: Argentina Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 80: Colombia Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 81: Colombia Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 82: Colombia Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 83: Middle East & Africa Point of Care Diagnostics Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)
Table 84: Middle East & Africa Point of Care Diagnostics Market Size and Forecast, By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 85: Middle East & Africa Point of Care Diagnostics Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)
Table 86: Middle East & Africa Point of Care Diagnostics Market Size and Forecast, By Mode Of Purchase (2020 to 2031F) (In USD Billion)
Table 87: Middle East & Africa Point of Care Diagnostics Market Size and Forecast, By Sample (2020 to 2031F) (In USD Billion)
Table 88: United Arab Emirates (UAE) Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 89: United Arab Emirates (UAE) Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 90: United Arab Emirates (UAE) Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 91: Saudi Arabia Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 92: Saudi Arabia Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 93: Saudi Arabia Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 94: South Africa Point of Care Diagnostics Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)
Table 95: South Africa Point of Care Diagnostics Market Size and Forecast By Technology/Platform (2020 to 2031F) (In USD Billion)
Table 96: South Africa Point of Care Diagnostics Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)
Table 97: Competitive Dashboard of top 5 players, 2025
Table 98: Key Players Market Share Insights and Analysis for Point of Care Diagnostics Market 2025
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Point of Care Diagnostics Market Share By Region (2025)
Figure 6: North America Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Point of Care Diagnostics Market Share By Country (2025)
Figure 8: US Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Point of Care Diagnostics Market Share By Country (2025)
Figure 13: Germany Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Point of Care Diagnostics Market Share By Country (2025)
Figure 21: China Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Point of Care Diagnostics Market Share By Country (2025)
Figure 28: Brazil Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Point of Care Diagnostics Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Point of Care Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Point of Care Diagnostics Market
Point of Care Diagnostics Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (23 September, 2026)
- Notify To Team (23 September, 2026)
- Report updation (24 September, 2026)
- Report Quality Check (24 September, 2026)
- Report Dispatch (25 September, 2026)
- Hard Copy
Recently Viewed Products
Global Point of Care Diagnostics Market Outlook, 2031
We are friendly and approachable, give us a call.